Orodispersible films containing ball milled aripiprazole-poloxamer®407 solid dispersions.


Journal

International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127

Informations de publication

Date de publication:
15 Feb 2020
Historique:
received: 21 08 2019
revised: 25 11 2019
accepted: 11 12 2019
pubmed: 18 12 2019
medline: 25 11 2020
entrez: 18 12 2019
Statut: ppublish

Résumé

This research aimed at developing ODFs containing an antipsychotic drug - aripiprazole (ARP). ARP, as a BCS II class molecule, requires enhancing its water solubility prior to formulating. Therefore, a solid dispersion of ARP - Poloxamer® 407 was prepared by ball milling, then incorporated into the films. It was found that co-processing led to an over 100-fold increase in drug solubility in comparison with pure drug. Moreover, ODFs with solid dispersion showed faster drug release (>95% below 15 min) and disintegration (<30 s), compared with raw ARP films. These results are believed to be due to the solubilization effect of poloxamer and enhanced wettability of the film. Films containing solid dispersions were found to possess smoother film surfaces and favorable mechanical properties - flexibility and strength. The ODF formulations, prepared by a casting method, were based on three different polymers (Kollicoat® IR, Kollicoat® Protect or PVA). It was found that not only the form of the incorporated drug, but also the type of film-forming polymer had an impact on the analyzed parameters. The use of PVA was beneficial in the film formulation with aripiprazole in comparison to other tested film-forming polymers.

Identifiants

pubmed: 31843552
pii: S0378-5173(19)31000-2
doi: 10.1016/j.ijpharm.2019.118955
pii:
doi:

Substances chimiques

Polyvinyls 0
Poloxamer 106392-12-5
Aripiprazole 82VFR53I78

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

118955

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Ewelina Łyszczarz (E)

Department of Pharmaceutical Technology and Biopharmaceutics, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, Poland. Electronic address: ewelina.lyszczarz@uj.edu.pl.

Justyna Hofmanová (J)

School of Pharmacy, University of Birmingham, Edgbaston B15 2TT, United Kingdom.

Joanna Szafraniec-Szczęsny (J)

Department of Pharmaceutical Technology and Biopharmaceutics, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, Poland; Department of Physical Chemistry and Electrochemistry, Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387 Krakow, Poland.

Renata Jachowicz (R)

Department of Pharmaceutical Technology and Biopharmaceutics, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, Poland.

Articles similaires

Vancomycin Polyesters Anti-Bacterial Agents Models, Theoretical Drug Liberation
Inclusion Bodies Solubility Recombinant Proteins Detergents Protein Denaturation

Elucidating ATP's role as solubilizer of biomolecular aggregate.

Susmita Sarkar, Saurabh Gupta, Chiranjit Mahato et al.
1.00
Adenosine Triphosphate Protein Aggregates Solubility Humans Protein Conformation

pH-responsive magnetic CuFe

Nadia Fattahi, Faranak Aghaz, Aram Rezaei et al.
1.00
Humans Hydrogen-Ion Concentration Breast Neoplasms Lignin Female

Classifications MeSH